Company intelligence / Profile preview

Axonova Pharma

Ownership: Private
Development stage: Preclinical

Overview

Axonova has developed a proprietary pipeline focused on novel small molecule drug candidates for neurodegenerative disorders. All known assets are in preclinical development. The company leverages local biodiversity to identify new bioactive compounds and licenses out assets for further clinical advancement. No clinical results have been published.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecules/chemical drugsNatural product-inspired compoundsBioactive ingredients from biodiversity sources
Industry: Biotech

Drug pipeline

3 assets

AXN-032

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Regional research partners in Mauritius/sub-Saharan Africa; specific names not disclosed

Beyond the preview

Go deeper on Axonova Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axonova Pharma.

Explore the full profile